![](https://fore.bio/wp-content/uploads/2021/09/2104_Fore_RnD_05_Fore_17B-scaled.jpg)
Press Release
Mar 11 2021
Fore Biotherapeutics Enters Pharma Business With BRAF Inhibitor as Lead Product
Read more
NEW YORK – By measuring the functional MAPK activity of different RAS mutations, researchers have developed a method they believe could help identify patients with RAS-mutated cancers likely to benefit from MEK inhibitors like trametinib (Novartis’ Mekinist).